- •Study aimed at utilizing artificial intelligence (AI)-based volumetric analysis on routine unstandardized T2-FLAIR scans in a multi-center study of 1002 people with relapsing-remitting MS (pwRRMS).
- •After propensity matching untreated pwRRMS had significantly greater 2-year thalamic atrophy when compared to treated pwRRMS (−1.2% vs. −0.3%, p = 0.044).
- •PwRRMS treated with high-efficacy DMTs had two-fold lower central atrophy rate when compared to pwRRMS treated on moderate-efficacy DMTs (3.5% vs. 7.0%, p = 0.001).
- •Non-harmonized MRI scans acquired through routine MS care can be utilized for measuring the neuroprotective DMT effect in a real-world setting.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Multiple Sclerosis and Related Disorders
- Multiple sclerosis.Lancet. 2018; 391: 1622-1636
- MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice.Nat. Rev. Neurol. 2020; 16: 171-182
- Imaging outcome measures for progressive multiple sclerosis trials.Mult. Scler. 2017; 23: 1614-1626
- Thalamic damage and long-term progression of disability in multiple sclerosis.Radiology. 2010; 257: 463-469
- Thalamic atrophy is associated with development of clinically definite multiple sclerosis.Radiology. 2013; 268: 831-841
- Deep gray matter volume loss drives disability worsening in multiple sclerosis.Ann. Neurol. 2018; 83: 210-222
- Thalamic atrophy in multiple sclerosis: a magnetic resonance imaging marker of neurodegeneration throughout disease.Ann. Neurol. 2018; 83: 223-234
- Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis.Neurology. 2018; 90: e1324-e1332
- Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: post hoc analysis of Phase 3 ozanimod trials.Eur. J. Neurol. 2021; 28: 3722-3730
- Impact of focal white matter damage on localized subcortical gray matter atrophy in multiple sclerosis: a 5-year study.Am. J. Neuroradiol. 2018; 39: 1480-1486
- Regional changes in thalamic shape and volume are related to cognitive performance in multiple sclerosis.Mult. Scler. 2021; 27: 134-138
- Attention and processing speed performance in multiple sclerosis is mostly related to thalamic volume.Brain Imaging Behav. 2018; 12: 20-28
- Disability improvement is associated with less brain atrophy development in multiple sclerosis.AJNR Am. J. Neuroradiol. 2020; 41: 1577-1583
- Inter-scanner reproducibility of brain volumetry: influence of automated brain segmentation software.BMC Neurosci. 2020; 21: 35
- Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis.Neuroimage Clin. 2017; 15: 769-779
- DeepGRAI (Deep gray rating via artificial intelligence): fast, feasible, and clinically relevant thalamic atrophy measurement on clinical quality T2-FLAIR MRI in multiple sclerosis.Neuroimage Clin. 2021; 30102652
- Thalamic atrophy measured by artificial intelligence in a multicentre clinical routine real-word study is associated with disability progression.J. Neurol. Neurosurg. Psychiatry. 2022;
- Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).Neurology. 1983; 33: 1444-1452
- Efficacy classification of modern therapies in multiple sclerosis.J. Comp. Eff. Res. 2021; 10: 495-507
- Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis.Pract. Neurol. 2015; 15: 273-279
- Accurate, robust, and automated longitudinal and cross-sectional brain change analysis.Neuroimage. 2002; 17: 479-489
- Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS.Mult. Scler. 2022; 13524585221097561
- Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.Mult. Scler. 2022; 13524585221076717
- Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis.Mult. Scler. 2020; 26: 312-321
- Age-dependent cut-offs for pathological deep gray matter and thalamic volume loss using Jacobian integration.Neuroimage Clin. 2020; 28102478
- Multisite MRI reproducibility of lateral ventricular volume using the NAIMS cooperative pilot dataset.J. Neuroimaging. 2022;
- Clinical feasibility of longitudinal lateral ventricular volume measurements on T2-FLAIR across MRI scanner changes.Neuroimage Clin. 2021; 29102554
- Manual and automated tissue segmentation confirm the impact of thalamus atrophy on cognition in multiple sclerosis: a multicenter study.Neuroimage Clin. 2021; 29102549
- Confounding by Indication in Clinical Research.JAMA. 2016; 316: 1818-1819
DeepGRAI Registry Group:
Principal Investigator: R. Zivadinov.
Co-Principal Investigator: Michael G. Dwyer
Study Steering Committee: R. Zivadinov, D. Silva, J. Riolo, MG. Dwyer.
Bristol Myers Squib: D. Silva, J. Riolo.
MRI Analysis Center: R. Zivadinov, N. Bergsland, D. Jakimovski, MG. Dwyer, C. Suchan, Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA
Myassar Zarif and Mark Gudesblatt, Comprehensive Multiple Sclerosis Care Center, Patchogue, NY, USA, Mitch Freedman, Raleigh Neurology, Raleigh, NC; Samuel Hunter, Advanced Neurosciences Institute, Franklin, TN; Stanley Cohan, Providence Brain and Spine Institute, Portland, OR; Keith Edwards, MS Center of NE New York, Latham, NY; Brian Steingo, Infinity Clinical Research, LLC, Sunrise, FL; Rana Zabad, University of Nebraska Medical Center, Omaha, NE; Matthew Baker, Collier Neurologic Specialists, Naples, FL; Martin Belkin, Michigan Institute for Neurological Disorders (MIND), Farmington Hills, MI; Pavle Repovic, Swedish Neuroscience Institute, Seattle, WA; Amir Mazhari, Dent Neurology, Buffalo, NY, Abby Chase, Saunders Medical Center, Wahoo, NE; Jason Silversteen, Christiana Care Health Services, Inc., Newark, NJ; Derek Smith, Thames Neurological Institute, Norwich, CT; Donald Negroski, Negroski Neurology, LLP, Sarasota, Sarasota, FL; Marc Feinberg, SFM Clinical Research LLC, Boca Raton, FL; Stephen Newman, Island Neurological Association, Plainview, NY; Gabriel Pardo, Oklahoma Medical Research Foundation, Oklahoma City, OK; Evanthia Bernitsas, Department of Neurology, Wayne State University, Detroit, MI; Robert Krug, Mt. Sinai Rehabilitation Hospital, Hartford, CT; Peter Wade, Mercy Medical Center, Springfield, MA; Jennifer Ruiz, Saint Mary's Hospital, Waterbury, CT; Bhupendra Khatri, Center for Neurological disorders at Ascension St. Francis, Milwaukee, WI; Bradley Jabour, Medical Imaging Center of Southern California, West Hollywood, CA; Tarun Singhal, Sturdy Memorial Hospital MS Center, Attleboro, MA; Flavia Nelson and Adam Carpenter, University of Minnesota, Minneapolis, MN; Francesca Bagnato and Margareta Clarke, Vanderbilt University, Nashville, TN; Jaqueline Nicholas and Andrew Smith, Ohio Health, MS Center, Riverside Methodist Hospital, Columbus, OH; Barry Singer, MS Center for Innovations in Care, Missouri Baptist Medical, St. Louis, MO
Search terms: disease modifying therapy, multiple sclerosis, thalamic atrophy, whole brain atrophy, lateral ventricle volume
Study was supported by a collaboration grant from Bristol Myers Squibb.
Statistical Analysis Performed by: Dejan Jakimovski; Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, 100 High Street, Buffalo, NY 14,203, Email: [email protected]